Regeneron beats estimates; seeks early FDA approval of Eylea

Leonard Schleifer, Regeneron Pharmaceuticals president and CEO, breaks down the company's better-than-expected earnings, and positive results from its phase three trials of a drug designed to improve vision in patients with diabetic macular edema.